The slip
PARKINSON RECEIPTno. 16637
31 Oct 2026, 21:42 UTCdopamine neurons, braak
predictionEFCAB13 in dopamine neurons tracks Braak Lewy-body stage
registereda861b6603d3e922a
discovery-0.17 p=0.663 n=9
replication+0.75 p=0.019 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.17, p 0.663)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTfa477edaef5a05bc8e1cd9b7…
follows 2f2588af5e70…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 16637: EFCAB13 in dopamine neurons, braak
- power
- full sample +0.35 (p 0.150, n 18), 95% CI -0.14 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.52 (p 0.026, n 18). not the mix.
- skeptic
- leave-one-out range +0.27 to +0.50, sign flips 0; without severely affected donors +0.35 (p 0.150, n 18). fragile.
- cell type
- strongest in microglia: +0.64 (p 0.0042, n 18) vs +0.35 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EFCAB13 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up EFCAB13 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.70 p 0.013 (needs p < 1.4e-4)